In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...
In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.
The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.
The approval includes patients whose disease progressed after treatment with endocrine therapy, which can cause ESR1 mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback